{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:34:42Z","timestamp":1790724882173,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2016.00743","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T14:14:19Z","timestamp":1464012859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library"],"prefix":"10.3389","volume":"7","author":[{"given":"Jie","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Auwaerter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1128\/AAC.00788-09","article-title":"Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.","volume":"54","author":"Barthold","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa1505425","article-title":"Randomized trial of longer-term therapy for symptoms attributed to Lyme disease.","volume":"374","author":"Berende","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/BF01713153","article-title":"Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes.","volume":"25","author":"Brorson","year":"1997","journal-title":"Infection"},{"key":"B4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1699-0463.1999.tb01594.x","article-title":"An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole.","volume":"107","author":"Brorson","year":"1999","journal-title":"APMIS"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18656","DOI":"10.1073\/pnas.0908236106","article-title":"Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline.","volume":"106","author":"Brorson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1128\/JCM.00486-15","article-title":"Rapid whole-genome sequencing of mycobacterium tuberculosis isolates directly from clinical samples.","volume":"53","author":"Brown","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"B7","author":"CDC","year":"2015a","journal-title":"Lyme Disease."},{"key":"B8","author":"CDC","year":"2015b","journal-title":"Post-Treatment Lyme Disease Syndrome."},{"key":"B9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects.","volume":"67","author":"Cholo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent.","volume":"2","author":"Chong","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1212\/01.WNL.0000284604.61160.2d","article-title":"A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.","volume":"70","author":"Fallon","year":"2008","journal-title":"Neurology"},{"issue":"e0117207","key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117207","article-title":"Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.","volume":"10","author":"Feng","year":"2015","journal-title":"PLoS ONE"},{"issue":"e49","key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.1053","article-title":"Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.","volume":"3","author":"Feng","year":"2014a","journal-title":"Emerg. Microb Infect."},{"issue":"e111809","key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111809","article-title":"An optimized SYBR Green I\/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi.","volume":"9","author":"Feng","year":"2014b","journal-title":"PLoS ONE"},{"issue":"62","key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00062","article-title":"Eradication of biofilm-like microcolony structures of Borrelia burgdorferi by daunomycin and daptomycin but not mitomycin C in combination with doxycycline and cefuroxime.","volume":"7","author":"Feng","year":"2016","journal-title":"Front. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.39.5.1127","article-title":"Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.","volume":"39","author":"Kersten","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.amjmed.2013.02.014","article-title":"Treatment trials for post-Lyme disease symptoms revisited.","volume":"126","author":"Klempner","year":"2013","journal-title":"Am. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1128\/AAC.45.9.2486-2494.2001","article-title":"In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.","volume":"45","author":"Kraiczy","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1212\/01.WNL.0000071227.23769.9E","article-title":"Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial.","volume":"60","author":"Krupp","year":"2003","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/cid\/cit810","article-title":"A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease.","volume":"58","author":"Lantos","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"e36","key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0010036","article-title":"Yeast model uncovers dual roles of mitochondria in action of artemisinin.","volume":"1","author":"Li","year":"2005","journal-title":"PLoS Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00124784-199623000-00017","article-title":"Underreporting of Lyme disease by Connecticut physicians, 1992.","volume":"2","author":"Meek","year":"1996","journal-title":"J. Public Health Manag. Pract."},{"issue":"40","key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-40","article-title":"Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis.","volume":"5","author":"Miklossy","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1600-0463.2004.apm1120110.x","article-title":"Induction of cystic forms by different stress conditions in Borrelia burgdorferi.","volume":"112","author":"Murgia","year":"2004","journal-title":"APMIS"},{"key":"B25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijfoodmicro.2010.04.001","article-title":"Use of natural antimicrobials to increase antibiotic susceptibility of drug resistant bacteria.","volume":"140","author":"Palaniappan","year":"2010","journal-title":"Int. J. Food Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1128\/JB.00011-12","article-title":"Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.","volume":"194","author":"Pogliano","year":"2012","journal-title":"J. Bacteriol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrmicro2714","article-title":"Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes.","volume":"10","author":"Radolf","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1590\/S0074-02762007000800017","article-title":"Evaluation of a modified culture medium for Borrelia burgdorferi sensu lato.","volume":"102","author":"Rodriguez","year":"2007","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"B29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IDR.S19201","article-title":"Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi.","volume":"4","author":"Sapi","year":"2011","journal-title":"Infect. Drug Resist."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","article-title":"Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids.","volume":"36","author":"Van Rensburg","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"e9582","key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009582","article-title":"Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation.","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS ONE"},{"key":"B32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nrd2972","article-title":"New medicines to improve control and contribute to the eradication of malaria.","volume":"8","author":"Wells","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1798","key":"B33","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1086\/588056","article-title":"Correction of a reference to clinical laboratory standards institute interpretive criteria.","volume":"46","author":"Wikler","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"e3","key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.3","article-title":"Persisters, persistent infections and the Yin-Yang model.","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microb. Infect."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"deposited":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T12:59:04Z","timestamp":1466513944000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fmicb.2016.00743\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":35,"URL":"https:\/\/doi.org\/10.3389\/fmicb.2016.00743","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}